HomeAI · summaries
Storia in 5 fonti
Sandoz bets big on biosimilars, aims to double group sales by 2035
Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfolio to 100 drugs by 2040. Sandoz targets mid-to-high single-digit sales growth from 2025 to 2030. Its net sales targets exclude potential contributions from generic GLP-1 drugs. Sandoz will invest an additional $300 million in a Slovenian biosimilar manufacturing facility.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
valor.globo.com
Sandoz pretende mais que dobrar vendas até 2035
Companhia revelou que está investindo cerca de US$ 300 milhões em uma nova fábrica de substâncias de medicamentos na Eslovênia
- ·
endpoints.news
Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia
Sandoz targets more than 100 biosimilars by 2040 under its Bio100 plan and will invest $300M in a new Ljubljana drug substance plant.
